Lexicon Pharmaceuticals, Inc.
LXRX
$1.12
-$0.03-2.61%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 58.43M | 31.21M | 31.08M | 5.23M | 3.64M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 58.43M | 31.21M | 31.08M | 5.23M | 3.64M |
| Cost of Revenue | 55.04M | 55.23M | 55.25M | 44.15M | 35.87M |
| Gross Profit | 3.39M | -24.02M | -24.17M | -38.92M | -32.23M |
| SG&A Expenses | 81.61M | 111.45M | 131.90M | 142.01M | 134.65M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 164.51M | 196.38M | 215.90M | 214.91M | 199.26M |
| Operating Income | -106.07M | -165.16M | -184.82M | -209.68M | -195.62M |
| Income Before Tax | -120.62M | -177.30M | -200.40M | -216.39M | -202.11M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -120.62 | -177.30 | -200.40 | -216.39 | -202.11 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -120.62M | -177.30M | -200.40M | -216.39M | -202.11M |
| EBIT | -106.07M | -165.16M | -184.82M | -209.68M | -195.62M |
| EBITDA | -105.47M | -164.60M | -184.28M | -209.12M | -195.03M |
| EPS Basic | -0.33 | -0.51 | -0.64 | -0.75 | -0.78 |
| Normalized Basic EPS | -0.19 | -0.30 | -0.38 | -0.47 | -0.48 |
| EPS Diluted | -0.33 | -0.51 | -0.64 | -0.75 | -0.78 |
| Normalized Diluted EPS | -0.19 | -0.30 | -0.38 | -0.47 | -0.48 |
| Average Basic Shares Outstanding | 1.45B | 1.40B | 1.28B | 1.16B | 1.05B |
| Average Diluted Shares Outstanding | 1.45B | 1.40B | 1.28B | 1.16B | 1.05B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |